Viewing Study NCT06483295


Ignite Creation Date: 2025-12-24 @ 2:08 PM
Ignite Modification Date: 2026-01-18 @ 6:23 PM
Study NCT ID: NCT06483295
Status: RECRUITING
Last Update Posted: 2025-05-28
First Post: 2024-03-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
Sponsor: Shanghai Chest Hospital
Organization:

Study Overview

Official Title: Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
Status: RECRUITING
Status Verified Date: 2025-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental issues. It emphasizes the importance of understanding the duration, severity, and factors affecting post-surgery symptoms like pain and coughing in patients. The research underlines the value of patient-reported outcomes (PROs) in enhancing postoperative care and survival rates through improved symptom monitoring and patient engagement. Utilizing internet technology, specifically a platform integrated with WeChat, the study aims to improve patient management and follow-ups post-discharge. The objective is to use mobile internet technology to build a high-quality prospective database on postoperative lung cancer patient outcomes, analyzing factors affecting postoperative discomfort and assessing the role of interactive platforms in improving patient care.
Detailed Description: Lung cancer is the leading cause of cancer-related deaths worldwide. In China, it has become the malignancy with the highest incidence and mortality rates, exacerbated by aging populations, smoking, and environmental issues. Post-major lung surgery, patients often experience reduced quality of life due to symptoms like pain and coughing. However, the duration, severity, and factors influencing these symptoms during recovery are not fully understood. Notably, recent attention has been given to the direct collection of patient-reported outcomes (PROs) for subjective symptom monitoring and improving patient care. Incorporating PRO monitoring in cancer patient follow-ups can reduce postoperative discomfort, enhance treatment tolerance and adherence, detect early relapses, and improve survival rates. Internet technology significantly expands information exchange frequency and efficiency. Management platforms based on internet mobile applications can enhance patient management compliance, enable intelligent follow-ups, and strengthen doctor-patient interaction. The investigators' hospital intends to utilize its internet hospital platform, integrated with WeChat (a Tencent application in China), for assisting in-patient management and post-discharge surveillance through automated multimedia material and PROs. WeChat, similar to Facebook and WhatsApp, is a multifunctional messenger app with over a billion active monthly users in China, effectively using an application already familiar to patients rather than introducing new ones.

This study aims to leverage mobile internet technology to transform traditional database construction, enhance the efficiency and accuracy of prospective database information collection, and establish a high-quality prospective database of postoperative lung cancer patient-reported outcomes. This will facilitate the analysis of factors influencing postoperative discomfort in patients and explore the role of interactive mobile internet technology platforms in improving postoperative PROs, thereby elevating the diagnostic and treatment standards in this field.

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: